01 / Scope
An approximate, safety-first timeline
Ibogaine is a psychoactive alkaloid derived primarily from Tabernanthe iboga, a West African shrub associated with Bwiti spiritual practice. Its principal active metabolite, noribogaine, lasts longer and helps explain why the experience can extend well beyond the most intense hours.
Descriptions of an ibogaine trip vary with health status, preparation, co-administered substances, setting, dose form, and whether someone is experiencing opioid withdrawal. Berkeley’s overview of ibogaine notes that the substance remains an area of active inquiry rather than an approved, routine treatment.
Some people encounter iboga root bark, a total alkaloid extract, or ibogaine hydrochloride. These are not interchangeable: root bark and total alkaloid extract can have less predictable composition than a measured isolated compound, and none removes the need for medical screening.
The usual duration is roughly 24 to 36 hours from ingestion to baseline recovery. A published discussion of trip duration similarly emphasizes that the active experience is longer than a short psychedelic session and that recovery can continue after the primary journey.
02 / Early onset
Hours 0 to 4: ingestion and early onset
During the first hours, ibogaine may produce a rising body load before a clear psychedelic shift. Nausea, trembling, dizziness, tremors, and a high-pitched buzzing sound can arrive first. Acoustic hypersensitivity may make ordinary conversation or room noise feel unusually prominent; some people also describe tinnitus.
The acute phase often begins one to two hours after ingestion. Reported onset can include closed eye visuals, shifting attention, and a sense that the central nervous system is becoming intensely activated. Accounts of what ibogaine feels like frequently distinguish this bodily onset from the later dreamlike material.
Nausea and purging are common. Vomiting may be triggered by head movements, standing attempts, or changes in physical posture. Purging is sometimes given spiritual meaning, but it is also a clinically relevant physical event that requires safe positioning and observation.
Ataxia can become severe early. Motor control may be so impaired that unassisted walking is difficult and hazardous. This is not a stage for moving around independently, even when a person feels mentally alert.
A flood dose is the term often used for a full psychoactive administration, while a booster dose refers to a smaller additional administration in some settings. Neither term establishes safety, and combining a flood dose with other drugs can materially increase risk.
“Hour by hour” is a map of uncertainty, not a schedule a person can rely on or reproduce.
03 / Peak
The acute visionary phase: hours 4 to 8
For many people, the acute phase develops into the most immersive portion of the experience. The visionary phase is often described as oneirophrenic or oneirogenic: a waking dream dominated by internally perceived scenarios rather than the open eye visuals more often associated with other psychedelic compounds.
Closed eye visuals may take the form of scenes, symbolic sequences, faces, memories, geometric environments, or narrative-like hallucinations. Open eye visuals can occur, but reports more often center on eyes-closed imagery and a waking dream that feels continuous and difficult to interrupt.
Many people describe a detached life review in which personal events, relationships, and patterns appear with unusual distance. A life review can include repressed memories without necessarily creating the same acute emotional re-traumatization people fear. However, response is individual, and an introspective experience is not a replacement for psychotherapy.
One treatment-day timeline describes this period as an extended peak rather than a quick rise and fall. Other experience narratives, including this overview of the ibogaine experience, reinforce how different people’s imagery and emotional tone can be.
What the peak can involve
- A prolonged acute phase with limited ability to control attention or imagery.
- Closed eye visuals and a waking dream, sometimes punctuated by open eye visuals.
- Nystagmus, nausea, tremors, and pronounced ataxia that undermine motor control.
- A life review that may feel objective, intense, or unexpectedly quiet.
Ataxia remains a key practical issue. During the peak, most people should not attempt to walk, shower, or use stairs. The combination of impaired balance, nausea, vomiting, and altered perception can make falls and aspiration hazards more serious.
04 / Evaluation
The evaluative or cognitive phase: hours 8 to 20
As the rapid imagery begins to recede, many reports shift toward a reflective phase. The cognitive phase may persist between hours 8 and 20, marked by slower thoughts, quiet appraisal, and a continued life review without the same density of visual material.
Some people feel profoundly introspective. Others feel physically depleted yet mentally unable to settle. The reflective phase can include insight about addiction, substance dependence, relationships, or past decisions, but insight alone is not integration and does not predict a particular outcome.
Ibogaine is metabolized by CYP2D6 into noribogaine, which has a significantly longer elimination half-life. Noribogaine is commonly described in research as affecting serotonin receptors and serotonin reuptake, with additional pharmacology that differs from ibogaine itself. The broader pharmacology of ibogaine is complex and should not be reduced to a simple “reset” narrative.
Research discussions also examine dopamine reuptake, the NMDA receptor, BDNF, and GDNF. These mechanisms may be relevant to neuroplasticity in dopamine pathways, but they do not establish that an experience will resolve cravings or addiction. Claims of sustained mood elevation and craving suppression require careful separation from individual testimony.
For someone in opioid withdrawal, perceived relief can be part of the experience, but the medical picture is complicated. Buprenorphine and methadone require particular interaction and timing assessment; neither should be stopped or changed based on an online timeline.
Descriptions of an ibogaine withdrawal timeline illustrate why withdrawal status changes the subjective account. They are not a substitute for individualized medical supervision, especially when opioid withdrawal and cardiovascular risk overlap.
05 / Descent
Residual stimulation and the recovery phase: hours 20 to 36
Residual stimulation often dominates the later timeline. The person may feel too exhausted to engage yet unable to sleep. Physical fatigue, tremors, and insomnia can persist, and sleep may be disrupted for up to 48 hours after ingestion.
During this part of the recovery phase, a person may seem closer to baseline while still having limited coordination, low appetite, and fragile attention. Noribogaine remains relevant after the acute phase, so the disappearance of obvious hallucinations does not mean physiological risk has ended.
A detailed account of a treatment day presents a similarly extended recovery window. Another account of what people expect during an ibogaine experience highlights how tiredness and wakefulness can coexist.
Residual stimulation is one reason the total duration matters. It may be tempting to treat hours 20 through 36 as finished, but physical fatigue, insomnia, and lingering ataxia can still affect decisions, hydration, mobility, and emotional tolerance.
06 / Somatic effects
Physical sensations and motor ataxia
Physical effects are central to an ibogaine experience, not incidental background. Ataxia occurs in nearly all reported full experiences and can render unassisted walking difficult for the first 12 to 18 hours. Motor control may remain unreliable after the strongest visionary phase has passed.
Nausea, vomiting, and purging are often reported in the onset and acute phase. People also describe tremors, altered heart rate, changes in blood pressure, weakness, and nystagmus when their eyes are open. Those observations are reasons for caution, not a measure of whether ibogaine is “working.”
The intensity of the acute phase can make basic needs difficult to manage. Professional medical supervision is relevant because observation must account for positioning, hydration decisions, aspiration risk, changing consciousness, and the possibility of arrhythmia alongside subjective distress.
Some public guides such as this broad ibogaine guide summarize the overlap of psychological and physical effects. A separate expectation-setting account similarly notes the long, taxing quality of the experience.
07 / Safety protocol
Cardiac safety and the importance of medical screening
Ibogaine can block hERG potassium channels and cause concentration-dependent QTc prolongation on an ECG. QTc prolongation matters because it can raise the risk of torsades de pointes and other dangerous cardiac arrhythmia events.
Before any proposed administration, medical screening should include a resting 12-lead ECG, review of medications and substances, a comprehensive metabolic panel, liver enzymes, and attention to electrolyte balance. Potassium levels and magnesium should be normal because disturbances can compound an arrhythmia risk.
Why continuous observation matters
Continuous cardiac monitoring, telemetry, and medical supervision are used in professional settings because the acute phase can overlap with peak blood plasma levels, QTc prolongation, changes in heart rate, and changes in blood pressure.
An ECG is not a one-time permission slip. Cardiac monitoring is necessary because risk can change as ibogaine and noribogaine are metabolized, and because co-intoxicants, substance dependence, dehydration, and underlying health conditions can alter the risk profile.
The U.S. Food and Drug Administration’s drug information explains the importance of regulated evidence and safety evaluation. Ibogaine is not FDA-approved for addiction, PTSD, depression, or any other indication.
An advocacy-oriented account of ibogaine access may reflect a different perspective, but access narratives should never override medical screening, ECG review, or cardiac monitoring. Safety claims must remain proportionate to the known risk.
For a fuller discussion of risks around use in severe alcohol-related contexts, see the independent material on ibogaine and extreme alcoholism. Alcohol use, withdrawal, medication interactions, electrolyte balance, and cardiovascular status all call for especially careful assessment.
08 / Next day
The gray day and psychological integration
The day after the primary journey is often called the gray day. It may involve flat affect, depleted energy, reduced sensory tolerance, physical fatigue, and a muted mood before any emotional afterglow becomes apparent. The gray day is not necessarily evidence of failure or success.
Integration means turning observations from a life review or reflective phase into safer, sustained actions over time. It can include psychotherapy, social support, sleep restoration, and structured attention to cravings and relapse risk. It is not guaranteed by the intensity of a psychedelic experience.
About this resource: the principles behind Ibogaine Trip are independence, clarity, and accuracy. We describe the hour-by-hour experience without presenting ibogaine as a treatment offer or a substitute for qualified medical advice.
People looking for structured explanatory material can review our information pathways, which are designed to help readers navigate terminology, uncertainty, and safety considerations without making clinical claims.
Some treatment narratives frame noribogaine, BDNF, GDNF, neuroplasticity, serotonin receptors, and dopamine reuptake as direct explanations for an afterglow or fewer cravings. These topics are scientifically interesting, but they remain distinct from proof that any individual’s addiction or substance dependence will improve.
A day-by-day expectation guide can help show why integration extends past the initial duration. The goal is not to forecast a universal outcome but to make the recovery phase easier to understand.
09 / Quick answers
Common questions about the timeline
How long does an ibogaine trip typically last?
An ibogaine journey typically lasts between 24 and 36 hours from initial ingestion to a return toward baseline. The acute visionary phase commonly lasts roughly 4 to 8 hours, while insomnia and physical fatigue can extend the recovery timeline.
What does the acute visionary phase feel like?
The acute phase is often characterized by closed eye visuals, a waking dream, internally focused hallucinations, heightened sound, and a detached life review. The visionary phase can be immersive and physically difficult rather than recreational or easily directed.
Is vomiting or purging common during an ibogaine session?
Yes. Nausea, vomiting, and purging are commonly reported during onset and peak periods. Head movement and posture changes can worsen nausea, while ataxia makes independent movement unsafe.
Why does ibogaine require continuous cardiac monitoring?
Ibogaine can produce QTc prolongation on an ECG and increase the risk of cardiac arrhythmia. Continuous cardiac monitoring, telemetry, electrolyte balance checks, and medical supervision address risks that cannot be judged from subjective experience alone.
What is the gray day after taking ibogaine?
The gray day describes the day after the primary experience, when flat affect, residual stimulation, physical fatigue, and insomnia may continue. It can precede an afterglow, but it should not be interpreted as a guaranteed stage or therapeutic result.
Can you walk or move around during the peak of an ibogaine experience?
Walking during the peak is generally unsafe because severe ataxia and reduced motor control are common. Nausea, tremors, nystagmus, and a strong acute phase can increase the risks of falls and injury.
Keep context in view
A timeline is information, not medical clearance.
Ibogaine is long-acting, variable, and medically hazardous. If you are comparing reports, keep the difference between subjective experience, clinical evidence, cardiac risk, and integration in view throughout the timeline.
Review safety considerations